Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064577 | 0.80 | METAP1 (0.37) | PBRM1CA1CA2HTR2AHTR2C | |
| SCHEMBL31040926 | 0.80 | ACHE (0.39) | CA1CA2HTR2AHTR2C | |
| SCHEMBL31040710 | 0.76 | CA1 (0.40) | CA1CA2HTR2AHTR2CHTR2B | |
| SCHEMBL31064355 | 0.76 | CA1 (0.40) | CA1CA2HTR2AHTR2CHTR2B | |
| SCHEMBL31394451 | 0.75 | HTR2A (0.45) | PBRM1CA1CA2HTR2AHTR2C | |
| SCHEMBL2729079 | 0.74 | PBRM1 (0.42) | PBRM1S100A4CA1CA2HTR2A | |
| SCHEMBL30553000 | 0.74 | PBRM1 (0.42) | PBRM1S100A4CA1CA2HTR2A | |
| SCHEMBL4419838 | 0.74 | PBRM1 (0.50) | PBRM1S100A4CA1CA2HTR2A | |
| SCHEMBL3982563 | 0.73 | PGR (0.54) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL31394732 | 0.72 | ADRA2A (0.40) | PBRM1CA1CA2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| EP-4592289-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| WO-2024199255-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | WO | disclosed |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173002-B2 | PRMT5 inhibitors and methods of use | PRMT5, PRMT1, PRMT7 | PBRM1 465/4885S100A4 3380/4885CA1 1921/4885 |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT7 | PBRM1 625/4885S100A4 3949/4885CA1 2115/4885 |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | PRMT5, PRMT6, PRMT1 | PBRM1 33/4885S100A4 3639/4885CA1 4405/4885 |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT1, PRMT5, PRMT6 | PBRM1 468/4885S100A4 3740/4885CA1 734/4885 |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT3 | PBRM1 326/4885S100A4 3489/4885CA1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.